Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer | OncLive

Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer

September 22, 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

The KEYNOTE-040 trial evaluated pembrolizumab (Keytruda) versus standard of care in patients with recurrent or metatstaic head and neck squamous cell carcinoma.

This was the first effort in a randomized setting to demonstrate benefit, though statistically, it did not meet its endpoint.


x